Press Release - Company Data

Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino Waiting Period in Relation to the Proposed Acquisition of Chelsea Therapeutics by Lundbeck
Posted 2014-06-06 00:10NAI Editing
today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") in connection with the previously announced Agreement and Plan of Merger

Lundbeck to Acquire Chelsea Therapeutics
Posted 2014-05-07 23:36NAI Editing
and H. Lundbeck A/S (Lundbeck) today announced that the companies have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
Posted 2014-02-27 23:53NAI Editing
which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERATM (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising aw

Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
Posted 2014-01-26 23:35NAI Editing
today announced that Joseph G. Oliveto has been named President and Chief Executive Officer and a member of the Company's Board of Directors, effective January 22, 2014. Mr.

Chelsea Therapeutics Announces First Patient Dosed in NORTHERA(TM) (droxidopa) Study 401 for the Treatment of Symptomatic nOH
Posted 2013-12-08 23:31NAI Editing
today announced that the first patient has been dosed in Study 401, a multi-center, multi-national, randomized, parallel-group, placebo-controlled, double-blind study of investigational drug NORTHERA

Chelsea Therapeutics Completes Public Offering of Common Stock
Posted 2013-11-17 23:36NAI Editing
a development stage pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products, announced today that it has completed its previously an

Chelsea Therapeutics Announces Submission of Additional Information for NORTHERA(TM) (Droxidopa) NDA
Posted 2013-08-13 23:18NAI Editing
today announced that it has submitted additional information to the U.S.

Chelsea Therapeutics Announces Update to NORTHERA(TM) (Droxidopa) NDA Filing
Posted 2013-07-28 23:38NAI Editing
today announced that the U.S.

Chelsea Therapeutics Announces FDA Acceptance of NORTHERA(TM) (droxidopa) NDA Resubmission
Posted 2013-07-16 23:32NAI Editing
today announced that the U.S.

Chelsea Therapeutics Resubmits New Drug Application for NORTHERA(TM) (droxidopa) for the Treatment of Symptomatic
Posted 2013-07-08 23:32NAI Editing
today announced that it resubmitted a New Drug Application (NDA) to the U.S.